Dabur India Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Strong Q1 with broad-based recovery: Consolidated revenue crossed INR 3,000 crores with 13.3% constant currency growth, led by a 20.6% surge in international business and an 8% India recovery driven by rural demand.
• Gross margins expanded, and the company is reinvesting: A 75 bps gross margin improvement, aided by moderating input inflation, was ploughed into a ~30% increase in A&P spend to rebuild brand investment that was cut during the inflationary period.
• A new therapeutics division targets allopathic doctors: A 400-person specialist team will advocate Dabur's healthcare portfolio to 70,000 allopathic practitioners, aiming for INR 150 crores in incremental revenue this year.
• Beverages were a drag, but the damage was contained: Unseasonal rains hit the summer-centric portfolio, yet Dabur's beverage decline was limited to 1.6% against a category drop of ~25%, cushioning the top line and helping the margin mix.
• What to watch next quarter: Whether the international business fully resolves its distributor changeover issues, the pace of Badshah and Hommade cross-pollination into new regions, and if the gross margin uptrend continues as strategic raw material inventories exhaust.

Demand Environment & Rural Recovery

• Rural rebound is real and Dabur is outpacing it: Rural FMCG volumes swung from minus 5 to plus 4, while Dabur's rural business grew 8%, ahead of the market, driven by its sub-stockist network in the Hindi heartland.
• Urban and modern trade are back: Modern trade grew ~18% after the Reliance dispute was resolved, and urban demand stayed healthy alongside rural, narrowing the growth gap between the two.
• No up-trading yet, but stability has returned: Price increase impacts have moderated into the base, and bridge packs are being pencilled in, though management sees no signs of consumers trading up.
• The recovery is demand-led, not inventory-led: Management confirmed the uptick was not due to inventory level changes from Q4 to Q1, pointing to genuine consumption improvement.

Mohit Malhotra: "And I don't see a reason why rural should not because if you look at around -- if I look at quarter 4 of financial year 21, rural was always the one which was leading the growth and urban was following. Now both urban and rural are kind of growing well."

Portfolio Performance

• Beverage weakness is margin-positive for the full year: The poor summer season means lower salience of the lower-margin beverage portfolio in the overall mix, which aids blended margins.
• Healthcare inventory normalization is complete: Abnormal bases have evened out, and the portfolio will now grow on a normal trajectory, though Chyawanprash declined ~9% in the non-season.

Strategic Initiatives: Therapeutics & Distribution

• A therapeutics division now targets allopathic doctors: A 400-person specialist team has been established to advocate Dabur's healthcare portfolio (baby care, branded ethicals, pure herbs) to 70,000 allopathic practitioners, in addition to the existing 70,000 ayurvedic practitioners, with an incremental revenue target of INR 150 crores this year.
• The logic is mainstream credibility: Management believes that without a tick from allopathic doctors, who are the mainstream practitioners in India, a healthcare portfolio cannot be driven at scale.
• Direct reach is expanding: The company plans to increase direct outlet coverage from 0.14 crore to 0.15 crore by fiscal year-end.
• Modern trade dispute resolved: The Reliance issue, triggered by one toothpaste SKU undercutting general trade, has been sorted out, and supplies have resumed, restoring modern trade growth.

Mohit Malhotra: "We feel that allopathic doctors are the mainstream practitioners in the country and without your portfolio getting a yes or a tick from the allopathic, you really can't drive healthcare in a country like India."

Foods Business & Badshah Integration

• Foods is scaling toward a INR 500 crore run-rate: Hommade grew 35% and Badshah grew 23%, with both businesses combined running at an annualized rate of INR 500 crores.
• Cross-pollination is the next leg: Hommade is strong in the North where Dabur's distribution is deep, while Badshah is strong in the West. The plan is to leverage Badshah's western distribution for Hommade and Dabur's northern network for Badshah, then expand Badshah into the West and South before moving North.
• D2C acquisition remains on the radar: Management is scouting for a synergistic D2C brand in healthcare, personal care, or skincare with an ayurvedic play, but will not acquire a dilutive brand that drags down EBITDA margins.

Mohit Malhotra: "The last thing we want to do is acquire a dilutive brand, which further takes down our EBITDA margin."

Margins & Input Costs

• Gross margin expanded 75 bps as input inflation eased: Material inflation moderated from high single digits to low single digits, with India inflation at ~0.5%, allowing the company to reinvest the gains.
• The reinvestment went entirely into A&P: Advertising spend rose ~30% as the company restored brand investment that had been cut during the inflationary period, and also shifted money from consumer and trade promotions into advertising.
• Food basket inflation is a near-term headwind: Spices inflation at 19% and fruit concentrate costs hit the summer-centric food portfolio, which is 25% of Q1 business; as the mix shifts to HPC and Healthcare in Q2/Q3, gross margin upside should improve.
• HPC raw material deflation is still to come: Strategic inventories of SLES and hydrocarbon-linked materials have delayed the benefit of lower input prices; as those inventories exhaust, further gross margin upsides will appear.
• Full-year margin guidance is 19% to 19.5%: Management expects to be at the higher end of this band, with a possibility of a positive surprise if inflation turns to deflation, though currency devaluation in international markets is a constraint on crossing 20%.

New Product Development & Innovation

• NPD is managed within power brand guardrails: Innovations like Hajmola variants (Limcola, Chatcola, Fantola) run on the same line, same bottle, with only cap colour and laminate differing, keeping supply chain complexity low.
• Baby Care is scaling fast: The portfolio exited at INR 20 crores last year and is targeting INR 50 crores this year, with management calling it a definite success.
• Cool King and Bae Fresh Gel are early-stage bets: Cool King, a tube-in-bottle with camphor crystals for perpetual cooling, launched in May in UP, North, and Bihar and clocked INR 6 crores; Bae Fresh Gel extends the Red franchise into a fresh-breath gel for youngsters.
• Innovation contribution target is 3-4% of overall business: For e-commerce, the target is around 10%, and around 34% of business should continue to come from innovations that are future growth pillars.

Mohit Malhotra: "First time there is a tube in a bottle which has got camphor crystals in it which provides cooling and perpetual cooling. No other player in the market has got this kind of a proposition."

Guidance & Commitments

Key Metrics